Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a cash flow conversion efficiency ratio of 0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥76.07 Million ≈ $11.13 Million USD) by net assets (CN¥1.17 Billion ≈ $170.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Beijing Sun Novo Pharmaceutical Research for the company's overall valuation and market capitalisation.
Beijing Sun Novo Pharmaceutical Research Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Beijing Sun Novo Pharmaceutical Research Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beijing Sun Novo Pharmaceutical Research Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Sun Novo Pharmaceutical Research Co Ltd ranked by their cash flow conversion efficiency. Explore Beijing Sun Novo Pharmaceutical Research earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZINKA LOGISTICS SOL LTD
NSE:BLACKBUCK
|
0.092x |
|
VIA Technologies Inc
TW:2388
|
0.028x |
|
Kailuan Energy Chemical Co Ltd
SHG:600997
|
0.020x |
|
Jingsu Jingshen Salt&Chem
SHG:603299
|
0.002x |
|
Lotte Rental Co Ltd
KO:089860
|
-0.077x |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
N/A |
|
Regional Container Lines Public Company Limited
BK:RCL
|
0.043x |
|
Zhejiang Jiahua Energy Chemical Industry Co Ltd
SHG:600273
|
0.025x |
Annual Cash Flow Conversion Efficiency for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. View current stock price of Beijing Sun Novo Pharmaceutical Research for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.23 Billion ≈ $180.50 Million |
CN¥93.21 Million ≈ $13.64 Million |
0.076x | +160.23% |
| 2024-12-31 | CN¥1.10 Billion ≈ $161.35 Million |
CN¥32.02 Million ≈ $4.69 Million |
0.029x | -66.94% |
| 2023-12-31 | CN¥1.06 Billion ≈ $154.71 Million |
CN¥92.86 Million ≈ $13.59 Million |
0.088x | -23.27% |
| 2022-12-31 | CN¥908.23 Million ≈ $132.90 Million |
CN¥103.96 Million ≈ $15.21 Million |
0.114x | -0.18% |
| 2021-12-31 | CN¥769.64 Million ≈ $112.62 Million |
CN¥88.25 Million ≈ $12.91 Million |
0.115x | -64.88% |
| 2020-12-31 | CN¥192.92 Million ≈ $28.23 Million |
CN¥62.99 Million ≈ $9.22 Million |
0.327x | -31.94% |
| 2019-12-31 | CN¥118.76 Million ≈ $17.38 Million |
CN¥56.97 Million ≈ $8.34 Million |
0.480x | -19.71% |
| 2018-12-31 | CN¥73.82 Million ≈ $10.80 Million |
CN¥44.11 Million ≈ $6.45 Million |
0.597x | +147.99% |
| 2017-12-31 | CN¥33.25 Million ≈ $4.87 Million |
CN¥8.01 Million ≈ $1.17 Million |
0.241x | -- |
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platfo… Read more